Parsonsgilbert2525

In the present study, we investigated the rate of cisplatin(CDDP)-induced acute kidney injury(CIA)and examined its association with various clinical factors in the combination therapy with CDDP for solid cancers. A total of 726 cases of solid cancer that had been indicated for the CDDP combination regimen from December 2012 to December 2013 were enrolled. CIA occurred in 48 cases(6.6%). The multivariate analysis revealed that diabetes, the regular use of non-steroidal anti- inflammatory drugs(NSAIDs), first dose of CDDP, and severe hyponatremia(≥Grade 3)within one week after CDDP administration were significantly associated with an increased risk for CIA, whereas magnesium supplementation was associated with a significantly reduced risk for CIA. Particularly, diabetes and cardiovascular disease were identified as risk factors for CIA in patients with esophageal and head and neck cancers. Based on the results of this survey, it is important to formulate preventive measures, evaluate risk factors, and respond rapidly.

Fertility preservation is important for Children, Adolescent and Young Adult(CAYA)cancer patients. Although a regional oncofertility network was established in Japan in 2012, regional inequality persists. This study was aimed at expanding the oncofertility network throughout Japan.

Oncologists, reproductive medicine specialists, and administrative officials from 24 regions, currently without a regional oncofertility network, conferred to discuss problems and strategies for network expansion.

Regional oncofertility networks had already been established in 4 of 24 regions. Consultation and support and a collaboration system between facilities and individual doctors were found in 13 and 14 regions, respectively. Regarding which organization should lead the network operation, the regions(number)chose the prefecture (10), prefectural cancer centers(10), and OB/GYN department of hospitals specializing in cancer treatment(9). Obstacles to establishing a regional oncofertility network were the lack of manpower(21), budget(19), know-how(16), and specialists( 12).

CAYA cancer patients need equal access to oncofertility networks, and a public support system is essential for preserving the fertility of cancer patients. We should organize a oncofertility network in association with prefectural administration. Medical staff training and supply of materials using the Oncofertility Consortium Japan system are required to promote the oncofertility network throughout Japan.

CAYA cancer patients need equal access to oncofertility networks, and a public support system is essential for preserving the fertility of cancer patients. We should organize a oncofertility network in association with prefectural administration. Medical staff training and supply of materials using the Oncofertility Consortium Japan system are required to promote the oncofertility network throughout Japan.We retrospectively investigated the use of oral hydromorphone for cancer pain. Nineteen patients treated for cancer pain with oral hydromorphone were reviewed in this study. Cancers had occurred in the gastrointestinal (n=4), lung(n=3), breast(n=2), bone and soft tissue(n=2), hematological(n=2), and others(n=6). The administered opioids before switching to hydromorphone were morphine, oxycodone, and tapentadol. The mean oral morphine equivalent daily dose (OMEDD)was 89.3 mg. The average dose of hydromorphone administered was 16.4 mg/day, and average NRS 10(numerical rating scale 0-10)scores of cancer pain before and after switching were 4.1 and 3.8, respectively, showing no significant differences. In this study, switching from other opioids to oral hydromorphone was feasible with an approved conversion ratio, ie, an oral hydromorphone-to-oral morphine ratio of 15. No severe adverse effects were observed. The oral hydromorphone extended-release formulation was administered every 24 h, as a tiny tablet formulation that is preferable owing to easy administration and adherence.The standard therapy for cancer should be basically performed on time. Nevertheless, COVID-19 pandemic has extensively affected cancer therapy in Japan. Under COVID-19 pandemic, medical resources in each hospital, incidence of infection in the community, and type and stage of cancer diseases, should totally be considered in performance of operation for cancer. Actually, in more than 40% of hospitals, cancer surgery was restricted, according to questionnaire survey, held by the Japanese Society of Gastroenterological Surgery. And also surgery for pancreatic, colorectal, esophageal and gastric cancer had preferred to other surgery. Generally, surgery for aggressive cancer, lacking in alternative therapy should be preferred. On the other hand, because the infection status in the community could rapidly change, policy for operation should be frequently reviewed.In 2019 later, the coronavirus disease 2019(COVID-19)pandemic have killed more than 1 million people worldwide. SARS-CoV2 cause severe pneumonia, the mortality is higher in cancer patients. Moreover, most of cancer patients are elderly and have other co-morbidities which are risk factors of COVID-19. It is still unclear that the relationship between anticancer treatments and COVID-19 are risk factors. Also, the fewer cancer diagnosis for cancer has suggested. The delay of cancer diagnosis will lead to presentation at more advanced stages and poor outcomes. Balancing the value of anticancer treatments with competing risks in COVID-19 pandemic is very difficult. The priorities for cancer care during COVID-19 pandemic affect cancer treatment decisions. However, anticancer treatments have the potential to cure should not be delayed. When treatment has been started, we need to consider the local healthcare system to triage the symptoms that is difficult to distinguish between COVID-19 and side effect of treatment, for example, febrile neutropenia and drug-induced pneumonitis. learn more To continue cancer treatment, education of infection prevention and protection, not only for medical staff but also for patient, are very important.Cancer patients with COVID-19 may be at increased risk of aggravation and death, and infectious risk of SARS-CoV-2 should be avoided as possible. It is a challenge to provide cancer therapy under circumstances where COVID-19 is rapidly spreading worldwide. Pharmacotherapy plays a central role for the treatment of advanced cancer. When a patient during anticancer therapy develops pneumonia, we need to cite, as differential diagnosis, anti-cancer drug induced lung injury as well as various pulmonary diseases such as viral pneumonia, bacterial pneumonia, pneumocystis pneumonia, and fungal pneumonia. In the current epidemic, COVID-19 pneumonia must also be kept in mind as well. Frequent symptoms of COVID-19 are fever, malaise, cough and dyspnea. Although bilateral multiple ground glass opacities with some consolidation of reticular shadow located at peripheral of lung are reported characteristics of COVID-19 imaging findings, it is difficult to diagnose COVID-19 pneumonia just by CT findings. It is also difficult to distinguish it from drug-induced lung injury in patients receiving cancer treatment.